Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Ginkgo Bioworks Holdings, Inc.
ISIN US37611X2099
|WKN A40KL9
Market cap (in EUR)
338 m
Country
United States
Sector
Healthcare
Overview
Description
Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Healthcare Healthcare Services Miscellaneous Healthcare United States
Financials
Key metrics
| Market capitalisation, EUR | 338 m |
| EPS, EUR | -5.04 |
| P/B ratio | 0.7 |
| P/E ratio | - |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | 151 m |
| Net income, EUR | -277 m |
| Profit margin | -183.81% |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.